In less than two months, Fibrocell Sciences Inc.'s LaViv (azficel-T) could become the second FDA-approved autologous cell therapy, following Dendreon Corp.'s prostate cancer vaccine Provenge (sipuleucel-T) last year. But the Exton, Pa.-based biotech isn't aiming for the medical market. Read More